drugset
drugset / Trial / NCT04128917

Triple Therapy With Tegoprazan in H. Pylori Positive Patients_PILOT

NCT04128917 ↗

Phase 3 Completed 102 enrolled HK inno.N Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study aims to compare safety and efficacy in an exploratory manner between a Tegoprazan triple therapy and a RAPAE01 triple therapy in H. pylori positive patients.

Timeline

Start
2020-01-21
Primary completion
2020-12-21
Completion
2021-01-29

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator RAPAE01 Unknown — Oral
Subject Tegoprazan Other / unclassified 50 mg Oral
Subject Tegoprazan Other / unclassified 100 mg Oral
Background Amoxicillin Other / unclassified 1000 mg Oral
Background Clarithromycin Small molecule 500 mg Oral

Indications

Helicobacter pylori infectious disease